A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
Phase of Trial: Phase II
Latest Information Update: 06 Oct 2017
At a glance
- Drugs E 06 (Primary)
- Indications Tinea pedis
- Focus Therapeutic Use
- Sponsors Sol-Gel Technologies
- 03 Oct 2017 Status changed from active, no longer recruiting to completed.
- 11 May 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Jan 2017 Status changed from not yet recruiting to recruiting.